Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Timetable
Microport Cardioflow Medtech
Nominal: 14.660 RT Quote
Open-offer-subscription Rate: 769x One Lot Success Rate: 7.5%

Microport Cardioflow Medtech Corporation is a medical device company in China focusing on the research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases.

The Group's self-developed first-generation transcatheter aortic valve implantation (TAVI) product, VitaFlowTM, was approved by the NMPA in July 2019 and subsequently commercialized in China in August 2019. As of 17 Jan 2021, there were five approved or commercialized TAVI products in China, among which, VitaFlowTM is the first one utilizing bovine pericardium as valve tissue, according to Frost & Sullivan.

The Group also launched its first generation in-house developed AlwideTM balloon catheter and AlpassTM catheter sheath as part of the VitaFlowTM offering, making it the only medical device company in China that has a comprehensive offering of in-house developed complementary TAVI procedural accessories.

As of 17 Jan 2021, VitaFlowTM II was the only TAVI product developed in China that had commenced a clinical trial in Europe. In addition to TAVI products, the Group currently have five transcatheter mitral valve (TMV) pipeline products strategically targeting all mainstream viable transcatheter valve therapy(2) (TVT) options for mitral regurgitation through inhouse development and collaboration with its global partners, namely 4C Medical and ValCare, each being a medical device company focusing on the R&D of mitral and tricuspid valve medical devices.

As of July 31, 2020, the Group had sold 872 units of VitaFlowTM—an average of over 70 units per month in the first year of its commercialization. TAVI procedures using VitaFlowTM had been performed at over 145 hospitals in China, most of which are Class IIIA Hospitals located at tier-one and tier-two cities, including 18 of the Top 20 TAVI Hospitals.

MarketHong Kong (Main Board)
Business NatureHealth Care
Board Lot1,000
Registrar & Transfer OfficeComputershare Hong Kong Investor Services
No. of Offer Shares206m shares
No. of International Offer Shares185m shares
No. of HK Offer Shares20.56m shares
Offer Price$11.10 - $12.20
Nominal ValueUS$ 0.000005 each
Stock Code2160
Joint SponsorsJ.P. Morgan Securities (Far East) Limited, Citigroup Global Markets Asia Limited, China International Capital Corporation Hong Kong Securities Limited
Joint Global CoordinatorsJ.P. Morgan Securities (Asia Pacific) Limited, Citigroup Global Markets Asia Limited, China International Capital Corporation Hong Kong Securities Limited
Joint Bookrunners and Joint Lead ManagersJ.P. Morgan Securities (Asia Pacific) Limited, J.P. Morgan Securities plc, Citigroup Global Markets Asia Limited, Citigroup Global Markets Limited, China International Capital Corporation Hong Kong Securities Limited
Application PeriodJan 26 (Tue) - Noon, Jan 29 (Fri)
Price Determination DateOn or Before 5pm, Jan 29 (Fri)
Result Announcement DateOn or Before Feb 3 (Wed)
Dispatch of Shares and Refund ChequesOn or Before Feb 3 (Wed)
Dealings in Shares commence onFeb 4, 2021. (Thu)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
ExecutiveChen Guoming, Yan Luying, Wu Guojia
Non-ExecutiveLuo Qiyi (Chairman), Zhang Junjie, Wu Xia
Independent Non-ExecutiveJonathan H. Chou, Jiang Hualiang, Sun Zhixiang
Microport (00853)45.59%
CR Holdings (01911)8.10%
CICC Kangrui7.67%
Wang Zheng6.34%
(Year ended Dec 31)
2020 *20192018
Gross Profit20,9856,302-
Pre-Taxed Profit(192,628)(144,522)(60,263)
Attributable Profit for the period(192,628)(144,522)(60,263)
EPS - Basic (RMB)(0.11)(0.08)(0.04)
* For the seven months ended July 31, 2020.
Attributable Loss (not more than)400 m
Offer Price$11.10 - $12.20
Capitalization$26,265m - $28,867m
Unaudited pro forma adj NAV / share$1.35 - $1.44
Assuming the offer price being at the mid-point of $11.65, the net proceeds raised would be HK$2,247.5m, of which:
* $674.2m (30.0%) to be allocated to our Core Product VitaFlowTM II ;
* $76.4m (3.4%) to be allocated to its first commercialized TAVI product, VitaFlowTM ;
* $606.8m (27.0%) will be allocated to the remaining products in its current product pipeline ;
* $337.1m (15.0%) will be used to fund the expansion of portfolio through collaboration with global enablers;
* $328.1m (14.6%) will be used to expand our production capacity and strengthen manufacturing capabilities for VitaFlow? and VitaFlow? II; and
* the balance of $224.7m (10.0%) as additional working capital.
Code Name Nominal Change %Change
02500VENUS MEDTECH-Bup62.0001.0001.639%
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
  Quote data is at least 15-min delayed,last updated: 14/04/2021 10:19
IPO Calculator
Subscription --
Result Announcement --      Listing --
Offer Price︰--
Currency :
Listing Price
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.003% and Stock Exchange trading fee of 0.005% (i.e. 1.008% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.